Sugi Predict

Sugi Predict / Compounds / SCHEMBL728499

SCHEMBL728499

SCHEMBL728499

Cc1cnc2c(c1)CC(=O)N2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 2/20 0.58
▸ KDR P35968 2/20 0.58
▸ CHEK1 O14757 1/20 0.58
▸ AURKA O14965 1/20 0.58
▸ DAPK3 O43293 1/20 0.58
▸ PRKD3 O94806 1/20 0.58
▸ MAP4K4 O95819 1/20 0.58
▸ NTRK1 P04629 1/20 0.58
▸ CSF1R P07333 1/20 0.58
▸ RET P07949 1/20 0.58
▸ MET P08581 1/20 0.58
▸ PDGFRB P09619 1/20 0.58
▸ PIM1 P11309 1/20 0.58
▸ FGFR1 P11362 1/20 0.58
▸ PDGFRA P16234 1/20 0.58
▸ FLT1 P17948 1/20 0.58
▸ LTK P29376 1/20 0.58
▸ GRK5 P34947 1/20 0.58
▸ MAP2K2 P36507 1/20 0.58
▸ FLT3 P36888 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6368447 0.84 CRBN (0.51) ABL1KDRCHEK1AURKADAPK3
SCHEMBL24722682 0.81 CRBN (0.43) ABL1KDRCHEK1AURKADAPK3
SCHEMBL13564019 0.81 MB (0.41) ABL1KDRCHEK1AURKADAPK3
SCHEMBL15595069 0.80 CHEK1 (0.39) ABL1KDRCHEK1AURKADAPK3
SCHEMBL13564008 0.78 ALDH1A1 (0.40) ABL1KDRCHEK1AURKADAPK3
SCHEMBL152602 0.78 GSK3B (0.58) ABL1KDRCHEK1AURKADAPK3
SCHEMBL20066164 0.78 CDK5 (0.58) ABL1KDRCHEK1AURKADAPK3
SCHEMBL5201194 0.78 ABL1 (0.58) ABL1KDRCHEK1AURKADAPK3
SCHEMBL23016925 0.78 ABL1 (0.58) ABL1KDRCHEK1AURKADAPK3
SCHEMBL29622130 0.78 MB (0.60) ABL1KDRCHEK1AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023096915-A1 MULTICYCLIC COMPOUNDS SLAP PHARMACEUTICALS LLC (US) 2023-06-01 — — WO disclosed
WO-2022140456-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS MEKANISTIC THERAPEUTICS LLC (US) 2022-06-30 — — WO disclosed
WO-2021159993-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2021-08-19 — — WO disclosed
WO-2021074279-A1 SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2021-04-22 — — WO disclosed
WO-2021013028-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-01-28 — — WO disclosed
EP-3741751-A1 HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF Guangzhou Healthquest Pharma Co., Ltd. (CN) 2020-11-25 — — EP disclosed
WO-2020216378-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2020-10-29 — — WO disclosed
EP-2594567-B1 HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF GUANGZHOU HEALTHQUEST PHARMA CO LTD (CN) 2020-07-29 — — EP disclosed
US-20170355695-A1 SMYD Inhibitors Epizyme, Inc. (US) 2017-12-14 — — US disclosed
US-20170247326-A1 Substituted Pyrrolidine Carboxamide Compounds Epizyme, Inc. (US) 2017-08-31 — — US disclosed
US-20090318411-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2009-12-24 — — US disclosed
WO-2009146406-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-12-03 — — WO disclosed
WO-2009112678-A2 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-09-17 — — WO disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
WO-2009016460-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS PFIZER INC. (US) 2009-02-05 — — WO disclosed
WO-2009011880-A2 HETEROCYCLIC MODULATORS OF PKB AMGEN INC. (US) 2009-01-22 — — WO disclosed
WO-2009011871-A2 THIADIAZOLE MODULATORS OF PKB AMGEN INC. (US) 2009-01-22 — — WO disclosed
EP-1560584-B1 FAB I INHIBITORS AFFINIUM PHARM INC (CA) 2009-01-14 — — EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221608-A1 PYRAZOLE COMPOUNDS BRAF, RAF1, NRAS ABL1 80/4885KDR 968/4885CHEK1 520/4885
US-20090318411-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, PIK3CG ABL1 986/4885KDR 2545/4885CHEK1 281/4885
US-20170355695-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 ABL1 2160/4885KDR 4784/4885CHEK1 2719/4885
US-20170247326-A1 Substituted Pyrrolidine Carboxamide Compounds SMYD3, SMYD2, SMURF2 ABL1 2427/4885KDR 4202/4885CHEK1 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.